224 related articles for article (PubMed ID: 29227304)
1. Cell-based immunotherapy in gynecologic malignancies.
Schaar B; Krishnan V; Tallapragada S; Dorigo O
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):23-30. PubMed ID: 29227304
[TBL] [Abstract][Full Text] [Related]
2. Cell-based immunotherapy in gynecologic malignancies.
Schaar B; Krishnan V; Tallapragada S; Chanana A; Dorigo O
Curr Opin Obstet Gynecol; 2019 Feb; 31(1):43-48. PubMed ID: 30540582
[TBL] [Abstract][Full Text] [Related]
3. T-cell target antigens across major gynecologic cancers.
Rodriguez-Garcia A; Minutolo NG; Robinson JM; Powell DJ
Gynecol Oncol; 2017 Jun; 145(3):426-435. PubMed ID: 28377094
[TBL] [Abstract][Full Text] [Related]
4. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
5. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.
Jazaeri A; Coleman RL; Sood AK; Frumovitz MM; Soliman PT; Shafer A; Cutrera JJ; Klinger M; Sharafi SE; Johnson CAL; Villanueva VF; Hinchcliff EM; Dickens A; Cain KE; Anderson JE; Lu KH; Westin SN
Gynecol Oncol; 2018 Nov; 151(2):374-380. PubMed ID: 30213435
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in Gynecologic Cancers: Are We There Yet?
Pakish JB; Jazaeri AA
Curr Treat Options Oncol; 2017 Aug; 18(10):59. PubMed ID: 28840453
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in Gynecologic Cancers: What We Know Now and Where We Are Headed.
Levinson K; Dorigo O; Rubin K; Moore K
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e126-e140. PubMed ID: 31099679
[TBL] [Abstract][Full Text] [Related]
8. Emerging Cellular Therapies for Cancer.
Guedan S; Ruella M; June CH
Annu Rev Immunol; 2019 Apr; 37():145-171. PubMed ID: 30526160
[TBL] [Abstract][Full Text] [Related]
9. A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity.
Singh NP; Yolcu ES; Taylor DD; Gercel-Taylor C; Metzinger DS; Dreisbach SK; Shirwan H
Cancer Res; 2003 Jul; 63(14):4067-73. PubMed ID: 12874008
[TBL] [Abstract][Full Text] [Related]
10. Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities.
Xu Y; Jiang J; Wang Y; Wang W; Li H; Lai W; Zhou Z; Zhu W; Xiang Z; Wang Z; Zhu Z; Yu L; Huang X; Zheng H; Wu S
Front Immunol; 2021; 12():725330. PubMed ID: 34386017
[TBL] [Abstract][Full Text] [Related]
11. Women's cancer: Advancing molecular and immunotherapy.
Dorigo O
Curr Probl Cancer; 2017; 41(1):7. PubMed ID: 28366203
[No Abstract] [Full Text] [Related]
12. Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T.
Yoon DH; Osborn MJ; Tolar J; Kim CJ
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364163
[TBL] [Abstract][Full Text] [Related]
13. Adoptive T-cell therapy for cancer: The era of engineered T cells.
Bonini C; Mondino A
Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future.
Blair AB; Murphy A
Curr Probl Cancer; 2018; 42(1):49-58. PubMed ID: 29501212
[TBL] [Abstract][Full Text] [Related]
15. Next generation T-cell therapy for genitourinary malignancies, part A: Introduction and current state of the art.
Pantuck M; Palaskas N; Drakaki A
Cancer Treat Res Commun; 2018; 17():8-12. PubMed ID: 30173005
[No Abstract] [Full Text] [Related]
16. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
Ikeda H
Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy.
Yu WD; Sun G; Li J; Xu J; Wang X
Cancer Lett; 2019 Jun; 452():66-70. PubMed ID: 30902563
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers.
Ferriss JS; Williams-Brown MY
Curr Treat Options Oncol; 2019 Aug; 20(10):75. PubMed ID: 31444655
[TBL] [Abstract][Full Text] [Related]
19. Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers.
Liu YL; Zamarin D
Curr Oncol Rep; 2018 Nov; 20(12):94. PubMed ID: 30421009
[TBL] [Abstract][Full Text] [Related]
20. Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.
Zamarin D; Jazaeri AA
Gynecol Oncol; 2016 Apr; 141(1):86-94. PubMed ID: 27016233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
